Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor

References

• Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med. 2013;2(6):907–915. doi:10.1002/cam4.14324403264
   PubMed Web of Science ®Google Scholar
• Reesink DJ, van de Garde EMW, Peters,BJM, et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. 2020;10(1):15822. doi:10.1038/s41598-020-72820-y32978455
   PubMed Web of Science ®Google Scholar
• Feliu J, Heredia-Soto V, Gironés R, et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2020;22(4):457–467. doi:10.1007/s12094-019-02167-y31240462
   PubMed Web of Science ®Google Scholar
• Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447–1455. doi:10.1200/JCO.2011.39.526922454424
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.87799047
   PubMed Web of Science ®Google Scholar
• Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14(12):2109–2119. doi:10.1016/j.jtho.2019.07.02531398540
   PubMed Web of Science ®Google Scholar
• Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–557. doi:10.1038/nrclinonc.2014.9624958182
   PubMed Web of Science ®Google Scholar
• Kim JH, Rha SY, Kim C, et al. Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Cancer Res Treat. 2010;42(4):217–224. doi:10.4143/crt.2010.42.4.21721253324
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs. metachronous metastases. Br J Cancer. 2010;103(2):159–164. doi:10.1038/sj.bjc.660573720551951
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi:10.1016/S1470-2045(19)30718-131908301
   PubMed Web of Science ®Google Scholar
• Chalkidou A, Macmillan T, Grzeda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. doi:10.1016/S1470-2045(20)30537-433387498
   PubMed Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.350128973074
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase ii, randomized study. J Clin Oncol. 2019;37(18):1558–1565. doi:10.1200/JCO.19.0020131067138
   PubMed Web of Science ®Google Scholar
• Fleckenstein J, Petroff A, Schäfers HJ, Wehler T, Schöpe J, Rübe C. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer. 2016;16:348. doi:10.1186/s12885-016-2379-x27255302
   PubMed Web of Science ®Google Scholar
• Tasca G, Dieci MV, Baretta Z, et al. Synchronous and metachronous breast and ovarian cancer: experience from two large cancer center. Front Oncol. 2020;10:608783. doi:10.3389/fonc.2020.60878333381461
   PubMed Web of Science ®Google Scholar
• Ma CX, Guan X, Wei R, et al. The distinction of clinicopathological characteristics, treatment strategy and outcome in colorectal cancer patients with synchronous vs. metachronous bone metastasis. Front Oncol. 2020;10:974. doi:10.3389/fonc.2020.0097432637357
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi:10.1016/S0140-6736(18)32487-530982687
   PubMed Web of Science ®Google Scholar
• Decoster L, Kenis C, Schallier D, et al. Geriatric assessment and functional decline in older patients with lung cancer. Lung. 2017;195(5):619–626. doi:10.1007/s00408-017-0025-228634893
   PubMed Web of Science ®Google Scholar
• Tuca A, Gallego R, Ghanem I, Gil-Raga M, Feliu J. Chemotherapy and targeted agents in the treatment of elderly patients with metastatic colorectal cancer. J Clin Med. 2020;9(12):4015. doi:10.3390/jcm9124015
   PubMed Web of Science ®Google Scholar
• Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. doi:10.1016/S1470-2045(16)30532-027789196
   PubMed Web of Science ®Google Scholar
• Li J, Wen Y, Xiang Z, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol. 2021;154:201–206. doi:10.1016/j.radonc.2020.09.04232980382
   PubMed Web of Science ®Google Scholar
• Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® patient registry. Radiat Oncol. 2018;13(1):26. doi:10.1186/s13014-018-0969-229439707
   PubMed Web of Science ®Google Scholar
• Arcidiacono F, Aristei C, Marchionni A, et al. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients. Br J Radiol. 2020;93(1115):20200645. doi:10.1259/bjr.2020064532822540
   PubMed Web of Science ®Google Scholar
• Sharma A, Duijm M, Oomen-de Hoop E, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2019;58(1):74–80. doi:10.1080/0284186X.2018.152198630280633
   PubMed Web of Science ®Google Scholar
• Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):117–125. doi:10.1016/j.ijrobp.2006.04.01316765528
   PubMed Web of Science ®Google Scholar
• Li H, Li J, Wang X, et al. Promising clinical outcome with long term follow-up after body Gamma knife stereotactic radiosurgery for patients with early stage non-small cell lung cancer. Front Oncol. 2018;8:618. doi:10.3389/fonc.2018.0061830622929
   PubMed Web of Science ®Google Scholar
• deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer. 2019;144(3):422–430. doi:10.1002/ijc.3179330098215
   PubMed Web of Science ®Google Scholar
• Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol. 2007;85(3):327–335. doi:10.1016/j.radonc.2007.11.00218037523
   PubMed Web of Science ®Google Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650. doi:10.1371/journal.pone.002865022174856
   PubMed Web of Science ®Google Scholar
• Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7:e50141. doi:10.1371/journal.pone.005014123251360
   PubMed Web of Science ®Google Scholar
• Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5(9):1283–1290. doi:10.1001/jamaoncol.2019.144931294762
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 2014;15(1):59–68. doi:10.1016/S1470-2045(13)70510-224331154
   PubMed Web of Science ®Google Scholar
• Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85. doi:10.3322/caac.2135827570942
   PubMed Web of Science ®Google Scholar